• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

网络药理学揭示了可重新用于治疗新冠肺炎的药物的多靶点作用机制。

Network pharmacology reveals multitarget mechanism of action of drugs to be repurposed for COVID-19.

作者信息

Alegría-Arcos Melissa, Barbosa Tábata, Sepúlveda Felipe, Combariza German, González Janneth, Gil Carmen, Martínez Ana, Ramírez David

机构信息

Facultad de Ingeniería y Negocios, Universidad de Las Américas, Sede Providencia, Santiago, Chile.

Departamento de Nutrición y Bioquímica, Facultad de Ciencias, Pontificia Universidad Javeriana, Sede Bogotá, Bogotá, Colombia.

出版信息

Front Pharmacol. 2022 Aug 17;13:952192. doi: 10.3389/fphar.2022.952192. eCollection 2022.

DOI:10.3389/fphar.2022.952192
PMID:36052135
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9424758/
Abstract

The coronavirus disease 2019 pandemic accelerated drug/vaccine development processes, integrating scientists all over the globe to create therapeutic alternatives against this virus. In this work, we have collected information regarding proteins from SARS-CoV-2 and humans and how these proteins interact. We have also collected information from public databases on protein-drug interactions. We represent this data as networks that allow us to gain insights into protein-protein interactions between both organisms. With the collected data, we have obtained statistical metrics of the networks. This data analysis has allowed us to find relevant information on which proteins and drugs are the most relevant from the network pharmacology perspective. This method not only allows us to focus on viral proteins as the main targets for COVID-19 but also reveals that some human proteins could be also important in drug repurposing campaigns. As a result of the analysis of the SARS-CoV-2-human interactome, we have identified some old drugs, such as disulfiram, auranofin, gefitinib, suloctidil, and bromhexine as potential therapies for the treatment of COVID-19 deciphering their potential complex mechanism of action.

摘要

2019年冠状病毒病大流行加速了药物/疫苗的研发进程,促使全球科学家联合起来,共同研发针对该病毒的治疗方案。在这项研究中,我们收集了有关严重急性呼吸综合征冠状病毒2(SARS-CoV-2)和人类蛋白质以及这些蛋白质如何相互作用的信息。我们还从公共数据库中收集了蛋白质-药物相互作用的信息。我们将这些数据表示为网络,以便深入了解两种生物体之间的蛋白质-蛋白质相互作用。利用收集到的数据,我们获得了网络的统计指标。数据分析使我们能够从网络药理学角度找出哪些蛋白质和药物最为相关。这种方法不仅使我们能够将病毒蛋白作为治疗2019冠状病毒病的主要靶点,还揭示了一些人类蛋白质在药物重新利用研究中也可能具有重要意义。通过对SARS-CoV-2-人类相互作用组的分析,我们确定了一些旧药,如双硫仑、金诺芬、吉非替尼、舒洛地尔和溴己新,它们可能是治疗2019冠状病毒病的潜在疗法,并解读了它们潜在的复杂作用机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36ae/9424758/56555128852a/fphar-13-952192-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36ae/9424758/6f59ca84893f/fphar-13-952192-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36ae/9424758/088dca2908c0/fphar-13-952192-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36ae/9424758/6a920fc0dfbe/fphar-13-952192-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36ae/9424758/56555128852a/fphar-13-952192-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36ae/9424758/6f59ca84893f/fphar-13-952192-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36ae/9424758/088dca2908c0/fphar-13-952192-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36ae/9424758/6a920fc0dfbe/fphar-13-952192-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36ae/9424758/56555128852a/fphar-13-952192-g004.jpg

相似文献

1
Network pharmacology reveals multitarget mechanism of action of drugs to be repurposed for COVID-19.网络药理学揭示了可重新用于治疗新冠肺炎的药物的多靶点作用机制。
Front Pharmacol. 2022 Aug 17;13:952192. doi: 10.3389/fphar.2022.952192. eCollection 2022.
2
Network-based drug repurposing for the treatment of COVID-19 patients in different clinical stages.基于网络的药物重利用用于治疗不同临床阶段的COVID-19患者。
Heliyon. 2023 Mar;9(3):e14059. doi: 10.1016/j.heliyon.2023.e14059. Epub 2023 Feb 24.
3
Molecular Binding Mechanism and Pharmacology Comparative Analysis of Noscapine for Repurposing against SARS-CoV-2 Protease.纳库巴因针对 SARS-CoV-2 蛋白酶的再利用的分子结合机制和药理学比较分析。
J Proteome Res. 2020 Nov 6;19(11):4678-4689. doi: 10.1021/acs.jproteome.0c00367. Epub 2020 Sep 4.
4
TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease (3CLpro): Potential therapeutic intervention to combat COVID-19.针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)主要蛋白酶(3CLpro)的TAT肽偶联重利用药物:对抗2019冠状病毒病(COVID-19)的潜在治疗干预措施
Arab J Chem. 2020 Nov;13(11):8069-8079. doi: 10.1016/j.arabjc.2020.09.037. Epub 2020 Oct 1.
5
The pharmacological mechanism of Huashi Baidu Formula for the treatment of COVID-19 by combined network pharmacology and molecular docking.基于网络药理学和分子对接联用探讨化湿败毒方治疗新型冠状病毒肺炎的药理机制
Ann Palliat Med. 2021 Apr;10(4):3864-3895. doi: 10.21037/apm-20-1759. Epub 2021 Mar 8.
6
Targeting hub genes and pathways of innate immune response in COVID-19: A network biology perspective.靶向 COVID-19 固有免疫反应的枢纽基因和通路:网络生物学视角。
Int J Biol Macromol. 2020 Nov 15;163:1-8. doi: 10.1016/j.ijbiomac.2020.06.228. Epub 2020 Jun 26.
7
Drug Discovery Strategies for SARS-CoV-2.针对 SARS-CoV-2 的药物研发策略。
J Pharmacol Exp Ther. 2020 Oct;375(1):127-138. doi: 10.1124/jpet.120.000123. Epub 2020 Jul 28.
8
Repurposing drugs against the main protease of SARS-CoV-2: mechanism-based insights supported by available laboratory and clinical data.重新利用药物对抗 SARS-CoV-2 的主蛋白酶:基于机制的见解,得到了现有实验室和临床数据的支持。
Mol Omics. 2020 Oct 1;16(5):474-491. doi: 10.1039/d0mo00057d. Epub 2020 Jul 22.
9
Designing a Network Proximity-Based Drug Repurposing Strategy for COVID-19.设计一种基于网络邻近性的新冠病毒药物再利用策略。
Front Cell Dev Biol. 2020 Oct 6;8:545089. doi: 10.3389/fcell.2020.545089. eCollection 2020.
10
In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.基于药物再利用的分子对接和动力学模拟预测 SARS-CoV-2 主要蛋白酶的潜在抑制剂的计算机预测。
J Infect Public Health. 2020 Sep;13(9):1210-1223. doi: 10.1016/j.jiph.2020.06.016. Epub 2020 Jun 16.

引用本文的文献

1
Delineating CYP2C19-mediated Interactions: Network Pharmacology Investigation of Ilaprazole and Clopidogrel Conventional Proton Pump Inhibitors.描述CYP2C19介导的相互作用:伊拉普利唑与氯吡格雷及传统质子泵抑制剂的网络药理学研究
Curr Drug Discov Technol. 2025;22(3):e15701638334244. doi: 10.2174/0115701638334244241224062453.
2
Deciphering the molecular nexus between Omicron infection and acute kidney injury: a bioinformatics approach.解析奥密克戎感染与急性肾损伤之间的分子联系:一种生物信息学方法。
Front Mol Biosci. 2024 Jul 4;11:1340611. doi: 10.3389/fmolb.2024.1340611. eCollection 2024.
3
Enzymatic Metabolic Switches of Astrocyte Response to Lipotoxicity as Potential Therapeutic Targets for Nervous System Diseases.

本文引用的文献

1
The Association of an Alpha-2 Adrenergic Receptor Agonist and Mortality in Patients With COVID-19.α-2肾上腺素能受体激动剂与COVID-19患者死亡率的关联
Front Med (Lausanne). 2022 Jan 4;8:797647. doi: 10.3389/fmed.2021.797647. eCollection 2021.
2
Structures and functions of coronavirus replication-transcription complexes and their relevance for SARS-CoV-2 drug design.冠状病毒复制-转录复合物的结构和功能及其与 SARS-CoV-2 药物设计的相关性。
Nat Rev Mol Cell Biol. 2022 Jan;23(1):21-39. doi: 10.1038/s41580-021-00432-z. Epub 2021 Nov 25.
3
Disulfiram use is associated with lower risk of COVID-19: A retrospective cohort study.
星形胶质细胞对脂毒性反应的酶促代谢开关作为神经系统疾病的潜在治疗靶点
Pharmaceuticals (Basel). 2024 May 16;17(5):648. doi: 10.3390/ph17050648.
4
A journey from molecule to physiology and tools for drug discovery targeting the transient receptor potential vanilloid type 1 (TRPV1) channel.从分子到生理学的历程以及靶向瞬时受体电位香草酸亚型1(TRPV1)通道的药物发现工具。
Front Pharmacol. 2024 Jan 24;14:1251061. doi: 10.3389/fphar.2023.1251061. eCollection 2023.
5
Antiandrogens as Therapies for COVID-19: A Systematic Review.抗雄激素作为COVID-19的治疗方法:一项系统综述
Cancers (Basel). 2024 Jan 10;16(2):298. doi: 10.3390/cancers16020298.
6
Polypharmacology: promises and new drugs in 2022.多靶标药物:2022 年的承诺与新药
Pharmacol Rep. 2023 Aug;75(4):755-770. doi: 10.1007/s43440-023-00501-4. Epub 2023 Jun 6.
7
Editorial: Antiviral drug discovery against pathogens of pandemic concern: Advancements in target site identification and structure-based drug development.社论:针对引起全球大流行病原体的抗病毒药物研发:靶点识别及基于结构的药物开发进展
Front Mol Biosci. 2023 Mar 9;10:1165208. doi: 10.3389/fmolb.2023.1165208. eCollection 2023.
8
Efficacy of Bromhexine versus Standard of Care in Reducing Viral Load in Patients with Mild-to-Moderate COVID-19 Disease Attended in Primary Care: A Randomized Open-Label Trial.氨溴索与标准治疗在降低基层医疗中轻症至中症新冠肺炎患者病毒载量方面的疗效:一项随机开放标签试验
J Clin Med. 2022 Dec 24;12(1):142. doi: 10.3390/jcm12010142.
9
Gold-Based Metal Drugs as Inhibitors of Coronavirus Proteins: The Inhibition of SARS-CoV-2 Main Protease by Auranofin and Its Analogs.基于金的金属药物作为冠状病毒蛋白抑制剂:金诺芬及其类似物对 SARS-CoV-2 主蛋白酶的抑制作用。
Biomolecules. 2022 Nov 11;12(11):1675. doi: 10.3390/biom12111675.
双硫仑的使用与降低 COVID-19 风险相关:一项回顾性队列研究。
PLoS One. 2021 Oct 28;16(10):e0259061. doi: 10.1371/journal.pone.0259061. eCollection 2021.
4
Mechanism of Anosmia Caused by Symptoms of COVID-19 and Emerging Treatments.COVID-19 症状导致嗅觉丧失的机制及新兴疗法。
ACS Chem Neurosci. 2021 Oct 20;12(20):3795-3805. doi: 10.1021/acschemneuro.1c00477. Epub 2021 Oct 5.
5
Impact of SARS-CoV-2 Infection (COVID-19) on Cytochromes P450 Activity Assessed by the Geneva Cocktail.新型冠状病毒感染(COVID-19)对细胞色素 P450 活性的影响评估(Geneva Cocktail 法)。
Clin Pharmacol Ther. 2021 Nov;110(5):1358-1367. doi: 10.1002/cpt.2412. Epub 2021 Sep 21.
6
Viral fibrotic scoring and drug screen based on MAPK activity uncovers EGFR as a key regulator of COVID-19 fibrosis.基于 MAPK 活性的病毒纤维化评分和药物筛选揭示 EGFR 是 COVID-19 纤维化的关键调节因子。
Sci Rep. 2021 May 27;11(1):11234. doi: 10.1038/s41598-021-90701-w.
7
Computational Identification of Potential Anti-Inflammatory Natural Compounds Targeting the p38 Mitogen-Activated Protein Kinase (MAPK): Implications for COVID-19-Induced Cytokine Storm.靶向p38丝裂原活化蛋白激酶(MAPK)的潜在抗炎天然化合物的计算鉴定:对COVID-19诱导的细胞因子风暴的启示
Biomolecules. 2021 Apr 29;11(5):653. doi: 10.3390/biom11050653.
8
Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods.通过分层计算机模拟/体外筛选方法鉴定出的具有抗SARS-CoV-2病毒活性的宿主导向型FDA批准药物
Pharmaceuticals (Basel). 2021 Apr 6;14(4):332. doi: 10.3390/ph14040332.
9
Artificial intelligence to deep learning: machine intelligence approach for drug discovery.人工智能到深度学习:药物发现的机器智能方法。
Mol Divers. 2021 Aug;25(3):1315-1360. doi: 10.1007/s11030-021-10217-3. Epub 2021 Apr 12.
10
Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia.抑制 TMEM16 蛋白的药物可阻断 SARS-CoV-2 刺突诱导的合胞体。
Nature. 2021 Jun;594(7861):88-93. doi: 10.1038/s41586-021-03491-6. Epub 2021 Apr 7.